Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics Inc (NASDAQ: INTS) is a clinical-stage biotechnology company pioneering novel intratumoral therapies designed to combat solid tumors through localized drug delivery and immune system activation. This news hub provides investors and industry professionals with timely, comprehensive updates on the development of INTS's innovative cancer treatments.
Access authoritative information about clinical trial progress, regulatory developments, and scientific advancements related to the company's DfuseRx technology platform. Our curated collection features essential updates including trial result announcements, partnership agreements, and research publications - all critical for evaluating INTS's position in the competitive oncology therapeutics market.
Key content categories include updates on INT230-6 clinical programs, technological enhancements to tumor saturation methods, and strategic collaborations with leading cancer research institutions. The resource serves as both a historical archive and real-time monitoring tool for tracking the company's progress in developing treatments for soft tissue sarcoma, triple-negative breast cancer, and other challenging malignancies.
Bookmark this page for streamlined access to verified information about INTS's scientific developments and corporate milestones. Check back regularly for objective reporting on how the company's localized treatment approach could potentially reshape cancer care paradigms while maintaining focus on patient safety outcomes.
Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotech company, has successfully raised $6.6 million in gross proceeds ($6.3 million net) through its At-the-Market (ATM) offering in July 2025. The company sold 19.9 million shares at an average price of $0.3323 per share, which was notably 10% higher than its June 2025 public offering price.
The funding extends Intensity's cash runway into the second half of 2026, supporting the advancement of its clinical trials for novel intratumoral cancer therapies. Following the ATM sales, the company's total outstanding common stock reached 46 million shares as of July 31, 2025.
Intensity Therapeutics (Nasdaq: INTS) has announced significant preclinical results for its drug candidate INT230-6 in treating Malignant Peripheral Nerve Sheath Tumors (MPNST). The study, conducted at Johns Hopkins University's Staedtke-Bai laboratory, demonstrated a 100% complete response rate in murine models after 21 days of treatment.
The research involved two groups of test subjects (n=5 each), with the INT230-6 treatment group achieving complete responses while the control group's tumors continued to grow. This marks the first time INT230-6 has been tested in neurological-specific tumors, with researchers noting that no other small molecule drug has achieved such results in their lab previously.
The company plans to conduct additional preclinical research with the Staedtke-Bai laboratory to explore INT230-6's potential in other neurological cancer models.Intensity Therapeutics (NASDAQ: INTS) announced that its Phase 3 INVINCIBLE-3 clinical trial of INT230-6 for treating metastatic soft tissue sarcomas will be presented at the ASCO 2025 Annual Meeting. The presentation will be delivered by Dr. Sant P. Chawla on May 31, 2025. INT230-6, an intratumoral therapy, has shown promising results in Phase 1/2 trials, demonstrating a 93% disease control rate and 21.3 months median overall survival in refractory metastatic sarcoma patients. The drug causes significant tumor necrosis and cyst formation with minimal adverse events. However, new enrollment for the Phase 3 study has been temporarily paused due to funding constraints, though treatment continues for currently enrolled patients.
Intensity Therapeutics (NASDAQ: INTS) has announced a collaboration with breast cancer survivor and author Christine Handy to raise awareness about early-stage breast cancer treatment options. Handy, whose book "Walk Beside Me" inspired the award-winning film "Hello Beautiful," will work with Intensity to develop educational resources about emerging therapies, including the company's investigational drug INT230-6.
The company is currently conducting the Phase 2 INVINCIBLE-4 trial for triple-negative breast cancer patients in pre-surgical settings. Additionally, Intensity will present a poster at the upcoming ASCO 2025 Annual Meeting about their Phase 3 INVINCIBLE-3 study, which evaluates INT230-6 as a monotherapy for soft tissue sarcomas.
Intensity Therapeutics (NASDAQ: INTS) and The Swiss Group for Clinical Cancer Research (SAKK) have received EMA authorization to expand their INVINCIBLE-4 Phase 2 study for INT230-6 into France. The study evaluates INT230-6 in early-stage, operable triple-negative breast cancer (TNBC) patients.
The trial, currently active in Switzerland, will randomize 54 patients to receive either two doses of INT230-6 followed by standard of care (SOC) immunochemotherapy, or SOC alone. The primary endpoint is pathological complete response in the tumor and affected lymph nodes. Initial results show promising tumor necrosis and inflammation after INT230-6 treatment. The expansion into France through Unicancer is expected to accelerate enrollment starting Q2 2025.
Intensity Therapeutics (NASDAQ: INTS) has announced a public offering priced at $0.75 per share, aiming to raise $2.35 million in gross proceeds. The offering includes 3,133,333 shares of common stock with accompanying Series B-1 and B-2 warrants.
The Series B-1 warrants have a 5-year term while Series B-2 warrants expire in 18 months, both with an exercise price of $0.85 per share. The offering, expected to close around April 28, 2025, is led by A.G.P./Alliance Global Partners with Brookline Capital Markets as co-placement agent.
The company plans to use the proceeds for patient enrollment in the INVINCIBLE-4 Study, treatment of existing patients in the INVINCIBLE-3 Study, and working capital purposes.